Iboga
PLANT
Tabernanthe iboga, Central African origins, Gabonese context, conservation, stewardship.
OPEN LANE →Iboga and Ibogaine, clearly sourced.
A public reference for the plant, the molecules, the evidence, the risks, the law, and the cultures that have carried Iboga for generations. Sources labeled by type and confidence. No dosing, no referrals, no miracle claims.
Try QT prolongation · Texas SB 2308 · Noribogaine FDA · Bwiti stewardship · Hamilton Morris
Find anything fast: search a topic, then follow the source labels into evidence, safety, policy, culture, media, or trackers.
I'm a researcher · clinician · journalist · policymaker · cultural reader · general reader
Last full review · 2026-05-18815 sources indexed4 claim checks2 corrections logged
Core terms
Iboga, Ibogaine, Noribogaine, and analogs are not the same thing.
Plant tradition, extracted alkaloid, metabolite, and biotech derivative are separate lanes. Evidence, law, safety, and cultural context change depending on which lane you are reading.
Ibogaine
ALKALOID
The psychoactive indole alkaloid studied for substance use and TBI, with serious safety and legal constraints.
OPEN LANE →Noribogaine
METABOLITE / DEVELOPMENT
A metabolite and current development focus. FDA permitted a phase I U.S. study in April 2026 — not approval.
OPEN LANE →Analogs
18-MC, TABERNANTHALOG, ...
Biotech derivatives tracked by molecule, evidence type, sponsor, and clinical status. Not interchangeable.
OPEN LANE →See the visual field guide: the four lanes, the safety risk map, evidence strength by condition, a history timeline, and the coverage audit — diagrams that help you read a claim before following it.
What's moving
Latest policy, research, media, and claim updates.
Rows are source-linked and dated so news, policy, and research signals do not blur into clinical proof.
Source type: LawConfidence: High
FDA allowed an early-phase noribogaine study to proceed in the U.S.
FDA announced that DemeRx NB may begin a closely monitored phase I noribogaine hydrochloride study for alcohol use disorder. This is not drug approval, not a finding of safety or effectiveness, and not patient access guidance.
Source type: LawConfidence: High
Oklahoma HB 3834 was approved by the governor.
Oklahoma's bill page shows HB 3834, the Oklahoma Breakthrough Therapy Act for ibogaine clinical trials, approved by the governor on May 12, 2026. It does not make ibogaine FDA-approved and does not erase federal Schedule I constraints.
Source type: LawConfidence: High
Texas remains the central public-funding case study.
Texas SB 2308 created a pathway for a selected consortium to conduct ibogaine drug development clinical trials and includes a subchapter that applies only if FDA approves ibogaine for a medical condition. Texas law is not proof of efficacy and does not mean treatment is available outside federal law and research controls.
Source type: LawConfidence: High
Tennessee HOPE Act materials describe proposed ibogaine drug-development trials.
The Tennessee fiscal note for HB 2075 / SB 2149 describes the Helping Open Pathways to Effective Treatment Act and proposed cohort-based ibogaine drug-development trials. The fiscal note is not clinical evidence and explicitly frames key activity around FDA approval and state/federal constraints.
Source type: MediaConfidence: Moderate
Podcast and interview discovery is now a standing intake lane.
The source catalog contains a growing podcast/interview directory and a dedicated Listening Library Curator role. Interview statements are not treated as facts until converted into claim records and traced to supporting sources.
Evidence by condition
Read the condition, then the quality of evidence.
The same template is used for each condition: human studies, sample sizes, design quality, outcomes, limitations, safety signals, and what is not proven.
| Condition | Evidence | Setting | What's not proven |
|---|---|---|---|
| Opioid use disorder | Evidence: Early humanEarly human and observational | Often uncontrolled, selection-biased, and setting-dependent; approved medications remain the essential comparator. | Ibogaine is not proven to cure opioid addiction. |
| Alcohol use disorder | Evidence: Very limitedVery limited human evidence | Phase I permission is safety-focused and does not establish efficacy. | Noribogaine is not FDA-approved for alcohol use disorder. |
| Traumatic brain injury | Evidence: Limited observationalLimited observational evidence | Open-label observational data can generate hypotheses but cannot establish broad efficacy. | Ibogaine is not proven as a general TBI treatment. |
| PTSD and trauma symptoms | Evidence: Limited observationalLimited observational evidence | Controlled studies with clear PTSD endpoints and adequate follow-up remain limited. | Ibogaine is not proven as a PTSD treatment. |
| Depression and mood symptoms | Evidence: Very limitedVery limited human evidence | Depression-specific controlled Ibogaine evidence remains limited. | Ibogaine is not proven as a depression treatment. |
| Parkinson's disease | Evidence: Case report onlySingle case report only | A single case cannot establish efficacy, generalizability, or safety. | Ibogaine is not proven as a Parkinson's treatment. |
| Withdrawal | Evidence: Limited observationalLimited observational evidence | Acute symptom change is easier to observe than durable relapse prevention. | Craving reduction or withdrawal relief is not the same as a cure. |
| Cravings | Evidence: Limited observationalLimited observational evidence | Acute symptom change is easier to observe than durable relapse prevention. | Craving reduction or withdrawal relief is not the same as a cure. |
Safety desk
Cardiac and interaction risk comes first.
Benefit claims are hard to interpret without the safety frame.
Published safety literature repeatedly centers the heart. QT/QTc prolongation, bradycardia, rhythm events, electrolyte abnormalities, medication interactions, polysubstance exposure, and emergency readiness shape how Ibogaine evidence is read.
- QT/QTc
- QT interval, QTc correction, bradycardia, arrhythmia concern, and electrolyte context appear repeatedly in safety literature.
- CYP2D6
- Metabolism and medication interactions matter when reading Ibogaine, Noribogaine, and analog claims.
- Electrolytes
- Withdrawal physiology, dehydration, electrolytes, cardiac risk, and polysubstance use can change safety interpretation.
Emergency readiness
Reputable research and clinical discussions emphasize screening, monitoring, exclusion criteria, medication review, and the ability to respond to cardiac or medical emergencies.
Open safety desk →Claim checks
Common statements get a verdict.
Cure language, FDA-approval claims, clinic success rates, and “natural means safe” claims need source checks before they are repeated.
“Ibogaine cures addiction.”
Evidence suggests possible effects on withdrawal, craving, and relapse for some people, but cure language outruns the evidence and hides risk.
Read the full check →“The FDA allowed Noribogaine, so it is approved.”
FDA allowed an early phase study to proceed. That is not approval and does not establish safety or effectiveness.
Read the full check →“Natural means safe.”
Iboga and Ibogaine can be natural and still carry serious cardiac and interaction risks.
Read the full check →Culture, stewardship, conservation
Iboga begins in Central African forest and living Bwiti traditions.
Public sources place Iboga in western equatorial Africa and describe older Central African knowledge systems before colonial and biomedical documentation. Public history, conservation, terminology, and stewardship can be discussed without treating private ceremony or lineage-held knowledge as internet content.